BLOG

How Are NK Cells Processed Before Infusion in Osaka?

Published 2026.10.22 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people read about NK cell therapy, they often focus on the infusion itself. Yet a large part of the process happens out of sight, in a laboratory, between the blood draw and the infusion. For patients considering treatment in Osaka, especially those traveling from abroad, it helps to understand what happens to your cells during that time and which questions are worth asking before you decide.

This article explains, in general terms, how NK cells are activated and expanded outside the body, why the cell processing facility matters, and what you may wish to discuss with a doctor at Grand Green Osaka Umekita Clinic. It is educational information, not medical advice, and it does not promise any outcome.

The short answer: your own cells are processed under a regulated system

In NK cell therapy as described by Grand Green Osaka Umekita Clinic, NK (natural killer) cells are obtained from a standard blood draw. They are then activated and expanded at a licensed cell processing facility and returned to your body by intravenous infusion. The aim is to give the body a larger number of more active NK cells than it may have on its own.

In Japan, this kind of treatment is provided as a self-pay (non-insured) medical service under the Act on the Safety of Regenerative Medicine and related rules. A treatment plan must be submitted to and accepted by the authorities, and the cell processing is carried out at a facility that meets legal requirements. Whether the therapy is suitable for you, and what it may cost, can only be confirmed after a consultation with a physician.

What happens to NK cells between the blood draw and the infusion?

The general flow is easy to describe, even though the laboratory work itself is highly specialized. Blood is collected in a way that is similar to a routine blood test. The sample is then sent to a cell processing facility, where NK cells are separated from other blood components, activated, and expanded in culture so that their number and activity increase. After the culture period, the cells are checked and prepared for infusion.

Because the cells come from you, the therapy is described as autologous. This is one reason the risk of rejection is considered low. It does not mean the treatment is free of risk. Temporary fever or fatigue may occur, and a doctor should explain other possible effects based on your own health.

Blood draw at the clinic, usually without hospitalization
Transport of the sample to the licensed processing facility
Activation and expansion of NK cells in culture
Quality checks before the cells are released
Return of the cells to your body by IV infusion

The exact timing, the number of sessions, and the schedule are decided individually. Please ask the clinic for current details rather than relying on general descriptions found online.

Why the cell processing facility matters to patients

Cells that will be returned to your body are a medical product made specifically for you, so the way they are handled is important. In general, a well-run processing facility works under written procedures, controls contamination risk, labels samples carefully so that cells are never confused between patients, and records each step. In Japan, facilities that process cells for regenerative medicine are subject to a licensing or notification system, and the clinic is expected to manage the process in line with its accepted plan.

As a patient, you are not expected to inspect a laboratory. However, you can reasonably ask the clinic to explain, in plain language, who is responsible for processing your cells, how identity and quality are checked, and what happens if a batch does not meet the required standard. A clear and patient answer is a good sign that the clinic takes transparency seriously.

Questions to ask before you decide

Preparing a short list of questions can make a consultation more productive, particularly when you are communicating in a second language or through an interpreter. You might consider asking the following.

Which facility will process my cells, and is it covered by the accepted regenerative medicine plan?
How are my cells identified and tracked from the blood draw to the infusion?
What quality checks are performed, and what happens if the cells cannot be used?
What are the known risks and side effects, and how are they managed?
What is the full cost, including any items that are charged separately, and is it self-pay?
How would this therapy fit with the standard treatment I am receiving or have received?

Be cautious about any explanation that sounds like a guarantee. NK cell therapy is a treatment option to learn about, not a cure, and the scientific evidence in this field is still developing. Published studies vary in design and size, and results from one study should not be generalized to every patient.

How this fits with standard cancer treatment

NK cell therapy is not presented as a replacement for surgery, chemotherapy, or radiation therapy. According to the clinic, it may be used alongside these treatments, and the clinic can coordinate with the medical institution that provides your standard care. Even so, your oncologist should be informed, and any decision about combining treatments should involve both doctors.

If you are traveling from abroad, it is wise to bring your diagnosis summary, imaging reports, and a list of current medications, ideally with translations. This allows the physician in Osaka to understand your situation before discussing whether the therapy could be considered at all.

Getting information in English and arranging a consultation

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, and it provides an information page for international patients so that you can review the basics in English before you make contact. A consultation is the place to confirm eligibility, fees, risks, schedule, and the role of the processing facility for your specific case.

In summary, the laboratory stage of NK cell therapy is a central part of the treatment, and it is reasonable to ask how it is managed. NK cell therapy in Japan is a self-pay treatment provided under the regenerative medicine law, and every decision about whether it is appropriate should be made together with a doctor who has reviewed your medical history.

From blood draw to infusion

1Blood drawStandard collection
2Processing facilityLicensed cell processing
3Activation and expansionCells cultured
4Quality checksBefore release
5IV infusionOwn cells returned

This figure is a conceptual diagram that summarizes the article

Learn more about NK Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›